← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. BMY
  3. P/E History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargets

BMY logoBristol-Myers Squibb Company (BMY) P/E Ratio History

Historical price-to-earnings valuation from 1990 to 2026

Current P/E
16.4
Undervalued
5Y Avg P/E
21.5
-24% vs avg
PE Percentile
35%
Below Avg
PEG Ratio
N/A
N/A
TTM EPS$3.56
Price$56.54
5Y PE Range11.9 - 68.8
Earnings Yield6.10%

Loading P/E history...

BMY Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
16.4vs21.5
-24%
Cheap vs History
vs. Healthcare
16.4vs22.2
-26%
Below Sector
vs. S&P 500
16.4vs25.2
-35%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 178% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 6, 2026, Bristol-Myers Squibb Company (BMY) trades at a price-to-earnings ratio of 16.4x, with a stock price of $56.54 and trailing twelve-month earnings per share of $3.56.

The current P/E is 24% below its 5-year average of 21.5x. Over the past five years, BMY's P/E has ranged from a low of 11.9x to a high of 68.8x, placing the current valuation at the 35th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.2x, BMY trades at a 26% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 178.0x.

Relative to the broader market, BMY trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BMY DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

BMY P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
PFE logoPFEPfizer Inc.
$151B19.5--4%
MRK logoMRKMerck & Co., Inc.
$280B15.60.73+8%
ABBV logoABBVAbbVie Inc.
$363B86.5--1%
LLY logoLLYEli Lilly and Company
$933B43.01.49+96%
JNJ logoJNJJohnson & Johnson
$541B38.8--58%
AZN logoAZNAstraZeneca PLC
$287B28.31.30+191%
GSK logoGSKGSK plc
$102B6.7Lowest0.47Best+348%Best
GILD logoGILDGilead Sciences, Inc.
$170B358.7--92%
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$75B17.42.75+8%
SNY logoSNYSanofi
$106B18.4--7%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

BMY Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2026 Q1$60.65$3.5617.0x-36%
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$53.94$3.4515.6x-41%
FY2025 Q3$45.10$2.9615.3x-43%
FY2025 Q2Mon Jun 30 2025 00:00:00 GM$46.29$2.4818.7x-30%
FY2025 Q1Mon Mar 31 2025 00:00:00 GM$60.99$2.6722.9x-14%
FY2023 Q4Sun Dec 31 2023 00:00:00 GM$51.31$3.8613.3x-50%
FY2023 Q3Sat Sep 30 2023 00:00:00 GM$58.04$3.9414.7x-45%
FY2023 Q2Fri Jun 30 2023 00:00:00 GM$63.95$3.7617.0x-36%
FY2023 Q1Fri Mar 31 2023 00:00:00 GM$69.31$3.4320.2x-24%
FY2022 Q4Sat Dec 31 2022 00:00:00 GM$71.95$2.9524.4x-8%
FY2022 Q3Fri Sep 30 2022 00:00:00 GM$71.09$3.0723.2x-13%
FY2022 Q2$77.00$3.0125.6x-4%

Average P/E for displayed period: 26.6x

Full BMY Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

See BMY's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is BMY Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare BMY vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

BMY — Frequently Asked Questions

Quick answers to the most common questions about buying BMY stock.

Is BMY stock overvalued or undervalued?

BMY trades at 16.4x P/E, below its 5-year average of 21.5x. At the 35th percentile of historical range, the stock is priced at a discount to its own history.

How does BMY's valuation compare to peers?

Bristol-Myers Squibb Company P/E of 16.4x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.

What is BMY's PEG ratio?

BMY PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

BMY P/E Ratio History (1990–2026)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.